By Priya Mehta, PharmD, Clinical Pharmacist. Medically reviewed by Dr. Maya Singh, MD, Board-Certified Internal Medicine, Obesity Medicine.
Marcus, 38, lives in Columbus, Ohio and works in logistics. In January he stepped on a clinic scale for the first time in two years: 261 pounds. His Fella provider started him on a low-dose tirzepatide protocol alongside a protein-forward meal plan and twice-weekly strength training. By July, he'd lost 42 pounds. "The shots help, obviously," he told his prescriber at a follow-up visit. "But I don't think I'd be anywhere close to this number without the food changes and the gym. It's both."
That combination, medication working alongside real lifestyle changes, is pretty much the whole story of how Fella works. But the details matter, and they're worth spelling out clearly.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Lifestyle & Adherence hub.
The Short Version
Fella is a men's telehealth weight-loss program. You get matched with a licensed prescriber, who evaluates whether a GLP-1 receptor agonist (typically tirzepatide or semaglutide) is appropriate for you, then writes a prescription if it is. The medication ships from a compounding pharmacy. You inject weekly at home. Alongside the prescription, the platform provides structured guidance on nutrition, exercise, and behavior change.
That's the skeleton. Here's the thing: the program works or doesn't work based on whether you actually do the lifestyle piece and whether you stay on therapy long enough for the drug to reach its full effect. More on both of those below.
Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications for safety, effectiveness, or quality. Any practical guidance about compounded products in this article reflects the standard clinical protocol for the underlying active ingredient, not a claim about the compounded formulation itself.
What the Medication Actually Does in Your Body
GLP-1 receptor agonists mimic a hormone your gut already produces called GLP-1. When you eat, your body releases GLP-1 to signal fullness, slow gastric emptying, suppress glucagon, and boost glucose-dependent insulin secretion. The synthetic version does all of that, just louder and longer.
Tirzepatide adds a second mechanism: GIP receptor agonism. Think of it like a stereo signal versus mono. Pre-clinical research suggests the GIP pathway may improve GI tolerability (fewer nausea episodes at higher doses) and affect how adipose tissue behaves. Whether that second receptor is the main reason tirzepatide's weight-loss numbers run ahead of semaglutide's in head-to-head trials is still debated, but the clinical results speak for themselves.
Semaglutide hits one receptor. Tirzepatide hits two. Both reduce appetite. Both slow digestion. Both require a weekly injection. The differences show up in degree, not in kind.
What the Trials Actually Show
Three studies matter most here:
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →SURPASS-2 (Frias et al., NEJM 2021) compared tirzepatide to semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Tirzepatide outperformed on both glycemic control and weight loss across all three dose arms.
SURMOUNT-2 (Garvey et al., Lancet 2023) evaluated tirzepatide in adults with obesity and type 2 diabetes over 72 weeks. The weight-loss numbers were large and consistent enough to change clinical conversations about what pharmacotherapy can realistically accomplish.
SELECT (Lincoff et al., NEJM 2023) studied cardiovascular outcomes of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity. This is the cardiovascular safety and benefit trial, the one that made insurers start paying attention.
A quick caveat that's actually specific and important: SURMOUNT-1 reported substantial differences in response within the same dose arm. Some people lost considerably more than the mean; some lost considerably less. Trial averages are compressed summaries of wide distributions. They're useful anchors, not personal predictions.
Why Real-World Results Differ from Trial Results
Clinical trials enforce adherence. They provide structured lifestyle interventions. They exclude patients with complicated medical histories. The real world does none of those things.
So real-world cohorts tend to show smaller average effects. The gap isn't enormous (the qualitative conclusion holds), but it's real. The biggest driver of that gap? Adherence. People stop taking the medication. They skip doses. They plateau at a low dose because they never titrated up.
The boring truth: patients who reach a maintenance dose and stay on therapy for 12 or more months consistently outperform those who quit within 90 days. Across the entire GLP-1 class, months on therapy at or near the maintenance dose is the strongest single predictor of long-term outcomes. Everything else matters less.
The Lifestyle Multiplier (It's Not Optional)
Every published GLP-1 weight-loss trial included a lifestyle component. SURMOUNT-1, STEP 1, the SURPASS series: all of them included calorie guidance and physical-activity recommendations alongside the drug. The published numbers you see? Those are the combined effect of medication plus lifestyle changes.
So when people ask "how does Fella work," part of the answer is: it works because it structures the non-medication inputs instead of leaving you to figure them out alone. The four most commonly underweighted inputs:
- Protein intake. GLP-1 drugs reduce appetite, which means total caloric intake drops. If protein drops with it, you lose more lean mass than necessary. Protein-forward eating protects muscle.
- Resistance training. Same logic. You're losing weight; make sure as much of it as possible is fat, not muscle. SURMOUNT-3 explicitly examined lifestyle plus pharmacotherapy for this reason.
- Sleep quality. Poor sleep disrupts hunger hormones, increases cortisol, and makes adherence harder. It's a force multiplier in the wrong direction.
- Hydration. Slowed gastric emptying plus reduced food volume means some patients chronically under-hydrate without realizing it, which amplifies nausea and fatigue.
Each one is a small lift to implement. Over months, they compound (no pun intended) into a substantial difference in outcomes.
What Actually Moves Your Individual Result
Here's where this falls apart if you're looking for a simple formula: the variables that affect your outcome include baseline BMI, glycemic status, age, sex, body composition, dietary patterns, sleep, resistance training, comorbidities, concurrent medications, and your own goals and constraints. No single variable dominates across all patients.
That's also what makes a documented log so valuable. Writing down your weight, your food, your training, your side effects, week by week, makes the variables visible. It turns a vague "it's not working" into a specific "my protein was under 80 grams four days last week and I skipped my Wednesday injection." Your prescriber can work with specifics. They can't work with feelings.
Open Questions Worth Watching
The evidence base for GLP-1 therapy is strong but still evolving in a few key areas:
- Long-horizon comparative-effectiveness data (tirzepatide vs. semaglutide over 2+ years)
- Cardiovascular outcome data for tirzepatide specifically (SELECT was semaglutide only)
- New incretin-targeted agents in development
- The regulatory and reimbursement landscape, which shifts faster than the science
Track peer-reviewed publications, not press releases. The published evidence is what holds up across the next decade.
Related reading in this cluster
- Does prozenith work for weight loss?
- Does the combipatch cause weight gain?
- How long does it take green tea to work?
- Is sweet tea better than pop?
- Saxenda For Weight Loss: Complete Guide
Frequently Asked Questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered belongs in a conversation with your prescriber. This article is general education, not individualized clinical guidance.
Where does this fit into my overall plan?
Most decisions in GLP-1 care become clearer in the context of your full picture: indication, comorbidities, lifestyle inputs, and goals. This article gives the general framework. The plan gets built with a prescriber who knows your specifics.
What if my situation is more complicated than what's described here?
Articles describe the general case. If your case feels unusual (multiple comorbidities, prior bariatric surgery, medications that interact), ask for a longer prescriber visit. Sometimes that means a referral to obesity medicine or endocrinology.
How often will the guidance here change?
The underlying mechanisms and foundational trial data are stable. Coverage, pricing, and regulatory specifics shift more often. Confirm anything time-sensitive with a current source.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How long before I notice results?
Most patients report appetite changes within the first two weeks. Measurable weight loss typically becomes clear by weeks 4 to 8, depending on starting dose and titration schedule. Meaningful body composition changes take longer, often 3 to 6 months.
Can I stop the lifestyle changes once the medication is working?
The medication and the lifestyle changes are not separable in the evidence. Every major trial tested them together. Patients who treat GLP-1 therapy as one input among several, rather than the entire strategy, tend to land closer to the trial averages. Drop the protein and the training and you'll lose more muscle relative to fat, which is the wrong trade.
Continue the Series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About This Article
Written by Priya Mehta, PharmD (Clinical Pharmacist). Medically reviewed by Dr. Maya Singh, MD (Board-Certified Internal Medicine, Obesity Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.